Canada Prostate Cancer Hormone Therapy Market Size, Share & Industry Analysis, By Drug Class (Gonadotropin Releasing Hormone Agonist {By Product Type [Lupron, Eligard, & Zoladex], By Route of Administration [Oral and Parenteral]}, Gonadotropin-Releasing Hormone Receptor Antagonist {By Product Type [FIRMAGON, ORGOVYX, & Others], By Route of Administration [Oral & Parenteral], Androgen Receptor Inhibitors [Oral & Parenteral], and Others, By Disease State (Metastatic Castration-Resistant Prostate Cancer, & Others), By Distribution Channel, and Regional Forecast, 2025-2032

The Canada prostate cancer hormone therapy market size was valued at USD 334.2 million in 2024. The market is projected to grow from USD 347.7 million in 2025 to USD 509.9 million by 2032, exhibiting a CAGR of 5.60% during the forecast period.

The Canada prostate cancer hormone therapy market is projected to witness stable growth in the coming years. The growth of the market is attributed to the rising prevalence of prostate cancer among Canadian men and the growing focus of prominent companies on the development of innovative hormonal therapies. Increasing research and development, as well as the expansion of pipeline candidates by key players, are anticipated to support growth.

Furthermore, strategic collaborations among key companies to enhance product offerings, followed by approval from regulatory bodies, are anticipated to drive market growth.

• For instance, in September 2025, the Canadian Cancer Society reported that prostate cancer is one of the most commonly diagnosed cancers in Canada among men.

Furthermore, the market is dominated by several key players, including Astellas Pharma Inc., Ferring, Johnson & Johnson, and AbbVie Inc., which focus on securing regulatory approvals and reimbursement from national authorities. These initiatives are anticipated to facilitate the adoption of hormonal therapies in the country.

MARKET DYNAMICS

MARKET DRIVERS:

Increasing Geriatric Population to Drive Market Growth

One of the key factors driving the Canada prostate cancer hormone therapy market growth is the increasing geriatric population. These ageing populations are at high risk of prostate cancer. This ageing population of men in Canada increases the need for safe and effective hormonal therapy, boosting the demand. Pharmaceutical companies are increasingly investing in research and development for safer alternative therapies to support the increasing prostate cancer hormone therapy demand.

• For instance, in November 2025, the Canadian Cancer Society published Canadian Cancer Statistics that reported that between the ages of 50- 84, prostate cancer was the second leading type of cancer diagnosed, accounting for 13-14% of total cases.

MARKET RESTRAINTS:

Emerging Alternatives to Hormonal Therapies to Impede Market Growth

Emerging alternatives to hormonal therapies for prostate cancer are anticipated to adversely impact the growth of the market over the forecast period. These emerging therapies reduce dependency on traditional hormone replacement, offering a safer profile and hampering the adoption of hormonal therapies. 

• For instance, in July 2024, Blue Earth Therapeutics collaborated with University College London (UCL) for a prostate cancer therapy trial. The candidate currently in Phase I/II trial was designed to evaluate the safety, tolerability, radiation dosimetry, and antitumor activity of the 225Ac-rhPSMA-10.1 in men with metastatic castrate-resistant prostate cancer who have previously responded to lutetium 177 (177Lu)-PSMA therapy. 

MARKET OPPORTUNITIES:

Rising Use of Combination Regimens to Offer Lucrative Growth Opportunities

The rising use of combination regimens offers Canada's prostate cancer hormone therapy market growth opportunities as it overcomes the limitations of hormonal therapies. These therapies provide a safer alternative and overcome the risk associated with the development of combination therapies. Additionally, technological advancements in drug delivery and regulatory approval by key governing bodies improve the safety and effectiveness of these regimens. Strategic collaborations among key operating players and an expanding clinical pipeline enable the rapid commercialization of these novel combination therapies, thereby expanding market opportunities.

• For instance, in July 2023, Health Canada granted a Notice of Compliance with Conditions (NOC/c) for Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.

MARKET CHALLENGES:

Stringent Regulations by Governing Bodies to Impose a Significant Challenge for Market Growth

The region has rigorous safety regulations and a framework in place for every stage of drug approval, health technology assessment, and reimbursement, all based on evidence-based processes. Manufacturers of these hormonal therapies undergo extensive clinical, safety, and quality evaluations and approvals. Failure to comply with these standard regulations often results in financial loss to pharmaceutical companies. These stringent regulations for outlining efficiency standards result in the halt of many clinical trials failing to compliance.

• For instance, in October 2024, ESSA Pharma Inc. terminated the Phase 2 clinical trial evaluating the randomization of masofaniten combined with enzalutamide versus enzalutamide as a single agent in patients with metastatic castration-resistant prostate cancer who were naïve to second-generation antiandrogens. The termination of the clinical trial was due to the low likelihood of meeting the study's prespecified primary endpoint. Such developments cause delays in product launches, which in turn affect commercial uptake and limit early revenue opportunities.

CANADA PROSTATE CANCER HORMONE THERAPY MARKET TRENDS:

Shift Toward Oral Hormonal Agents is a Prominent Trend Observed in Market

One of the most prominent Canada prostate cancer hormone therapy market trends observed is the shift toward oral hormonal agents. The trend aligns with the country’s inclination toward a decentralized healthcare delivery model. These oral therapies facilitate adherence and improve patient outcomes. Owing to this, several key pharmaceutical companies have capitalized on this trend by developing more advanced oral hormonal formulations that target precision androgen signaling. Emphasizing these advantages, many key companies are developing new products and focusing on their subsequent approval by governing bodies to commercialize this opportunity.

• For instance, in October 2023, Sumitomo Pharma Canada, Inc. received approval from Health Canada for ORGOVYX (relugolix), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of advanced prostate cancer.

Download Free sample to learn more about this report.

Segmentation Analysis

By Drug Class

Androgen Receptor Inhibitors Led Market Due to Their Enhanced Efficacy in Blocking Prostate Tumor Growth

Based on the drug class, the market is classified into gonadotropin releasing hormone (GnRH) agonists, gonadotropin releasing hormone (GnRH) receptor antagonists, androgen receptor inhibitors, and others.

The androgen receptor inhibitors segment dominated the Canada prostate cancer hormone therapy market share. The dominance of the drug class is attributed to their enhanced efficacy in blocking prostate tumor growth with safety. These agents offer more selective and potent inhibition in comparison to traditional hormonal therapies. Additionally, improved patient outcomes drive rapid clinical utilization. Furthermore, recent approval from regulatory bodies reinforces their robust market dominance and propels segmental growth.

• For instance, in August 2025, Bayer Inc. received marketing authorization from Health Canada for its oral androgen receptor inhibitor (ARi) NUBEQA (darolutamide) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).

On the other hand, the gonadotropin releasing hormone (GnRH) receptor antagonist segment is the fastest-growing segment with a 4.4% CAGR during the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Disease State

Supportive Regulatory Ecosystem and Reimbursement Initiatives Fueled Metastatic Castration-Resistant Prostate Cancer Segment Expansion

In terms of disease state, the market is categorized into metastatic castration-resistant prostate cancer, non-metastatic castration-resistant prostate cancer, and others.

In 2024, the metastatic castration-resistant prostate cancer segment accounted for the largest share of the market 2024. In 2025, the segment is anticipated to dominate with a 49.3% share. The dominance of the segment is due to the increasing prevalence of metastatic castration resistance prostate cancer and longer patient survival in hormone-sensitive disease. Additionally, the supportive regulatory ecosystem and reimbursement initiatives in Canada accelerated the adoption of hormonal therapies for metastatic castration-resistant prostate cancer. Additionally, increasing research and development initiatives for the development of effective hormonal therapies further support the segment's growth.

• For instance, in August 2025, Bayer AG received marketing authorization from Health Canada for an additional indication of NUBEQA (darolutamide) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC).

The non-metastatic castration-resistant prostate cancer segment is expected to grow at a CAGR of 9.6% over the forecast period. 

By Distribution Channel

Hospital Pharmacies Dominated Market as They are Principal Centers for Distribution of Hormonal Therapies

In terms of distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies.

The hospital pharmacies segment accounted for the largest share of the market in 2024. In 2025, the segment is anticipated to dominate with a 57.6% share. These hospital pharmacies are the primary centers for distributing these hormonal therapies, which are administered under the clinical supervision of an oncology specialist. Additionally, increasing collaborations among hospitals and other stakeholders to raise awareness is expected to drive the growth of the segment. 

• For instance, in September 2025, Alberta Blue Cross collaborated with the Prostate Cancer Center to raise awareness about prostate cancer and the importance of timely exams for early detection.

The drug stores & retail pharmacies segment is expected to grow at a CAGR of 6.1% over the forecast period. 

COMPETITIVE LANDSCAPE

Key Industry Players:

Leading Prostate Cancer Hormone Therapy Companies Emphasize Strategic Collaborations to Maintain Their Dominance

The Canada prostate cancer hormone therapy market exhibits a semi-concentrated structure, with a few companies actively operating worldwide. These players are actively involved in regulatory approvals, product innovation, research and development, and the expansion of pipeline candidates for the market. They actively invest in the advancement of these therapies to offer a wide array of products in their portfolio.

Johnson & Johnson, Astellas Pharma Inc., and Bayer AG are some of the significant players in the market. Strategic collaborations among key players, such as pipeline expansion, research and development for new product launches, and their subsequent approvals, are a few characteristics that support these players' dominance.

• For instance, in August 2025, Bayer AG received marketing authorization from Health Canada for its oral androgen receptor inhibitor (ARi) NUBEQA (darolutamide) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).

Apart from this, other prominent players in the market include Ferring and Tolmar Inc., among others. These companies are undertaking various strategic initiatives, such as investments in strategic collaborations and product launches, to enhance their market presence.

LIST OF KEY CANADA PROSTATE CANCER HORMONE THERAPY COMPANIES PROFILED:

• Astellas Pharma Inc. (Japan)
• Johnson & Johnson (U.S.)
• Bayer AG (Germany)
• AbbVie Inc.(U.S.)
• Ferring (Switzerland)
• Tolmar, Inc. (U.S.)
• Knight Therapeutics Inc. (Canada)
• TerSera Therapeutics LLC. (U.S.)

KEY INDUSTRY DEVELOPMENTS:

• June 2025: Astellas Pharma Canada, Inc. announced that the Ontario Drug Benefit Program funded XTANDI (enzalutamide) under the Exceptional Access Program for the treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence (BCR) at high risk of metastasis (high-risk BCR).
• January 2025: Novartis AG expanded access to Pluvicto (lutetium (177Lu) vipivotide tetraxetan injection) to eligible patients in Ontario, for treatment indicated for adult patients with prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer (mCRPC) who have received at least one androgen receptor pathway inhibitor (ARPI) and at least one taxane-based chemotherapy
• March 2024: Johnson & Johnson completed the acquisition of Ambrx Biopharma, Inc. The development strengthened the company’s commitment to innovation in prostate cancer, specifically in the development of ARX517, a potential PSMA-targeting ADC for the treatment of metastatic castration-resistant prostate cancer.
• January 2024: Astellas Pharma Canada, Inc. submitted a supplemental New Drug Application to Health Canada for XTANDI (enzalutamide) in a new prostate cancer treatment setting.
• November 2023: Astellas Pharma Inc. acquired Propella Therapeutics, Inc. This development provided the company access to PRL-02 (abiraterone decanoate), a next-generation androgen biosynthesis inhibitor being developed to treat prostate cancer.

REPORT COVERAGE

The Canada prostate cancer hormone therapy market analysis delivers a comprehensive study of market size & forecast by all the market segments included in the report. It includes a detailed overview of market dynamics and major trends in the market that offer significant growth avenues. It also provides overviews of technological advancements, product development, pipeline analysis, and key industry developments, including mergers & acquisitions, as well as strategic insights into market growth. The market research report also provides a detailed competitive landscape, including market share and profiles of key operating players, along with their key product portfolios.

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation